Updated on 2025/03/31

写真a

 
TAKEDA Midori
 
Organization
Research Field in ? Assistant Professor
Title
Assistant Professor

Degree

  • 博士（医学） ( 2016.3   岡山大学 )

Research History

  • Kagoshima University   Research Field in Integrated Studies, Integrated Arts and Sciences Area ?   Assistant Professor

    2019.4

  • Kagoshima University   Research Field in Medicine and Health Sciences, Medical and Dental Sciences Area Center for Chronic Viral Diseases   Assistant Professor

    2018.4 - 2019.3

Professional Memberships

  • 日本分子生物学会

  • 日本ウイルス学会

  • 日本肝臓学会

 

Papers

  • Ai Toyodome, Seiichi Mawatari, Hiromi Eguchi, Midori Takeda, Kotaro Kumagai, Ohki Taniyama, Sho Ijuin, Haruka Sakae, Kazuaki Tabu, Kohei Oda, Masanori Ikeda, Akio Ido .  Analysis of the susceptibility of refractory hepatitis C virus resistant to nonstructural 5A inhibitors .  Scientific Reports14 ( 1 ) 16363   2024.7Reviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)   Publisher：Springer Science and Business Media LLC  

    Abstract

    Resistance-associated substitutions (RASs) of hepatitis C virus (HCV) affect the efficacy of direct-acting antivirals (DAAs). In this study, we aimed to clarify the susceptibility of the coexistence of nonstructural (NS) 5A Q24K/L28M/R30Q (or R30E)/A92K RASs, which were observed in patients with DAAs re-treatment failure and to consider new therapeutic agents. We used a subgenomic replicon system in which HCV genotype 1B strain 1B-4 was electroporated into OR6c cells derived from HuH-7 cells (Wild-type [WT]). We converted WT genes to NS5A Q24K/L28M/R30Q/A92K or Q24/L28K/R30E/A92K. Compared with the WT, the Q24K/L28M/R30Q/A92K RASs was 36,000-fold resistant to daclatasvir, 440,000-fold resistant to ledipasvir, 6300-fold resistant to velpatasvir, 3100-fold resistant to elbasvir, and 1.8-fold resistant to pibrentasvir. Compared with the WT, the Q24K/L28M/R30E/A92K RASs was 640,000-fold resistant to daclatasvir and ledipasvir, 150,000-fold resistant to velpatasvir, 44,000-fold resistant to elbasvir, and 1500-fold resistant to pibrentasvir. The Q24K/L28M/R30E/A92K RASs was 816.3 times more resistant to pibrentasvir than the Q24K/L28M/R30Q/A92K RASs. Furthermore, a combination of pibrentasvir and sofosbuvir showed therapeutic efficacy against these RASs. Combination regimens may eradicate HCV with NS5A Q24K/L28M/R30E/A92K RASs.

    DOI： 10.1038/s41598-024-67169-5

    Scopus

    PubMed

    Other Link： https://www.nature.com/articles/s41598-024-67169-5

  • Jiazhou Li, Midori Takeda, Mikiko Imahatakenaka, Masanori Ikeda .  Identification of dihydroorotate dehydrogenase inhibitor, vidofludimus, as a potent and novel inhibitor for influenza virus .  Journal of Medical Virology96 ( 1 ) e29372   2024.1Reviewed International journal

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

    Influenza A virus (IAV) infection causes respiratory disease. Recently, infection of IAV H5N1 among mammals are reported in farmed mink. Therefore, to discover antivirals against IAV, we screened a compound library by using the RNA-dependent RNA polymerase (RdRp) assay system derived from H5N1 IAV including a drug-resistant PA mutant (I38T) and a viral polymerase activity enhancing PB2 mutant (T271A). Upon screening, we found vidofludimus can be served as a potential inhibitor for IAV. Vidofludimus an orally active inhibitor for dihydroorotate dehydrogenase (DHODH), a key enzyme for the cellular de novo pyrimidine biosynthesis pathway. We found that vidofludimus exerted antiviral activity against wild-type and drug-resistant mutant IAV, with effective concentrations (EC50 ) of 2.10 and 2.11 μM, respectively. The anti-IAV activity of vidofludimus was canceled by the treatment of uridine or cytidine through pyrimidine salvage synthesis pathway, or orotic acid through pyrimidine de novo synthesis pathway. This indicated that the main target of vidofludimus is DHODH in IAV RdRp expressing cells. We also produced recombinant seasonal IAV H1N1 virion and influenza B virus (IBV) RdRp assay system and confirmed vidofludimus also carried highly antiviral activity against seasonal IAV and IBV. Vidofludimus is a candidate drug for the future threat of IAV H5N1 infection among humans as well as seasonal influenza virus infection.

    DOI： 10.1002/jmv.29372

    Scopus

    PubMed

  • Masaaki Toyama, Norikazu Sakakibara, Midori Takeda, Mika Okamoto, Koichi Watashi, Takaji Wakita, Masaya Sugiyama, Masashi Mizokami, Masanori Ikeda, Masanori Baba .  Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly .  Virus Research   2019.10Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assemblyReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Midori Takeda, Masanori Ikeda, Shinya Satoh, Hiromichi Dansako, Takaji Wakita, Nobuyuki Kato .  Rab13 Is Involved in the Entry Step of Hepatitis C Virus Infection .  Acta Medica Okayama   2016.4Rab13 Is Involved in the Entry Step of Hepatitis C Virus InfectionReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Hiroki Hiramoto, Hiromichi Dansako, Midori Takeda, Shinya Satoh, Takaji Wakita, Masanori Ikeda, Nobuyuki Kato .  Annexin A1 negatively regulates viral RNA replication of hepatitis C virus .  Acta Medica Okayama   2015.4Annexin A1 negatively regulates viral RNA replication of hepatitis C virusReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Youki Ueda, Midori Takeda, Kyoko Mori, Hiromichi Dansako, Takaji Wakita, Hye-Sook Kim, Akira Sato, Yusuke Wataya, Masanori Ikeda, Nobuyuki Kato .  New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication .  PLOS ONE   2013.8New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA ReplicationReviewed

    　More details

    Language：English   Publishing type：Research paper (scientific journal)  

  • Midori Takeda, Masanori Ikeda, Kyoko Mori, Masahiko Yano, Yasuo Ariumi, Hiromichi Dansako, Takaji Wakita, Nobuyuki Kato .  Raloxifene inhibits hepatitis C virus infection and replication .  FEBS Open Bio   2012.8Raloxifene inhibits hepatitis C virus infection and replicationReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

  • Midori Takeda, Masanori Ikeda, Yasuo Ariumi, Takaji Wakita, Nobuyuki Kato .  Development of hepatitis C virus production reporter assay systems using two different hepatoma cell lines .  Journal of General Virology   2012.7Development of hepatitis C virus production reporter assay systems using two different hepatoma cell linesReviewed

    　More details

    Authorship：Lead author   Language：English   Publishing type：Research paper (scientific journal)  

▼display all

MISC

  • 肝炎治療剤の新しい知見

    池田 正徳, 武田 緑, 濱田 智仁, 池内 秀幸, 稲生 佳菜子, 小林 勉, 岸川 洋介

    Medical Science Digest   45 ( 1 )   38 - 39   2019.1

    　More details

    Language：Japanese   Publisher：(株)ニュー・サイエンス社